Regulation of human eosinophil serine protease 1-like enzyme
AssigneeBayer Aktiengesellschaft
InventorYonghong Xiao
Life of this patent
Estimating the term…
Abstract
A human eosinophil serine protease 1-like enzyme, cDNA, and reagents that regulate the enzyme can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, asthma, COPD, airway allergy, and osteoporosis.
Claims65
A cDNA encoding a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof.
An expression vector comprising a polynucleotide which encodes a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof.
A host cell comprising an expression vector which encodes a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof.
A purified polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof.
A fusion protein comprising a polypeptide consisting of an amino acid sequence selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:2 and (b) biologically active variants thereof.
A method of producing a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof, comprising the steps of:
- culturing a host cell comprising an expression vector that encodes the polypeptide under conditions whereby the polypeptide is expressed;
- and
- isolating the polypeptide.
A method of detecting a coding sequence for a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof, comprising the steps of:
- hybridizing a polynucleotide comprising 11 contiguous nucleotides selected from the group consisting of (a) the complement of the nucleotide sequence shown in SEQ ID NO:1, (b) a polynucleotide that hybridizes under stringent conditions to (a), (c) a polynucleotide having a nucleic acid sequence that deviates from the nucleic acid sequences specified in (a) and (c) due to the degeneration of the genetic code, and (d) a polynucleotide that represents a fragment, derivative, or allelic variation of a nucleic acid sequence specified in (a) to (c) to nucleic acid material of a biological sample to form a hybridization complex;
- and
- detecting the hybridization complex.
A method of detecting a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof, comprising the steps of:
- contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex;
- and
- detecting the reagent-polypeptide complex.
A method of screening for agents that can regulate an activity of a human eosinophil serine protease 1-like enzyme, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof;
- and
- detecting binding of the test compound to the polypeptide, wherein a test compound that binds to the polypeptide is identified as a potential agent for regulating the activity of the human eosinophil serine protease 1-like enzyme.
A method of screening for therapeutic agents that can regulate an enzymatic activity of a human eosinophil serine protease 1-like enzyme, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof;
- and
- detecting the enzymatic activity of the polypeptide, wherein a test compound that increases the enzymatic activity of the polypeptide is identified as a potential therapeutic agent for increasing the enzymatic activity of the human eosinophil serine protease 1-like enzyme, and wherein a test compound that decreases the enzymatic activity of the polypeptide is identified as a potential therapeutic agent for decreasing the enzymatic activity of the human eosinophil serine protease 1-like enzyme.
A method of screening for therapeutic agents that can regulate an activity of a human eosinophil serine protease 1-like enzyme, comprising the steps of:
- contacting a test compound with a product encoded by a polynucleotide comprising a nucleotide sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof;
- and
- detecting binding of the test compound to the product, wherein a test compound that binds to the product is identified as a potential therapeutic agent for regulating the activity of the human eosinophil serine protease 1-like enzyme.
A method of reducing an activity of a human eosinophil serine protease 1-like enzyme, comprising the step of:
- contacting a cell comprising the human eosinophil serine protease 1-like enzyme with a reagent that specifically binds to a product encoded by a polynucleotide comprising a nucleotide sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof, whereby the activity of the human eosinophil serine protease 1-like enzyme is reduced.
A pharmaceutical composition, comprising:
- a reagent that specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:2 and (b) biologically active variants thereof;
- and
- a pharmaceutically acceptable carrier.
The pharmaceutical composition of claim 50 wherein the reagent is an antibody.
A pharmaceutical composition, comprising:
- a reagent that specifically binds to a product of a polynucleotide comprising a coding sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- an expression vector encoding a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof;
- and
- a pharmaceutically acceptable carrier.
A method of treating a disorder selected from the group consisting of asthma, COPD, airway allergy, and osteoporosis, comprising the step of:
- administering to a patient in need thereof a therapeutically effective dose of a reagent that inhibits a function of a human eosinophil serine protease 1-like enzyme, wherein the human eosinophil serine protease 1-like enzyme comprises an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, and 58 and (b) biologically active variants thereof, whereby symptoms of the disorder are ameliorated.
An isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide encoding a protein that comprises the amino acid sequence of SEQ ID NO:2, 56, or 58, (b) a polynucleotide comprising the sequence of SEQ ID NO:1, (c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) or (b);
- (d) a polynucleotide having a nucleic acid sequence that deviates from the nucleic acid sequences specified in (a)-(c) due to the degeneration of the genetic code, and (e) a polynucleotide that represents a fragment, derivative, or allelic variation of a nucleic acid sequence specified in (a)-(d).
A preparation of antibodies that specifically bind to a polypeptide selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:2, 56, or 58 and (b) biologically active variants thereof.
An antisense oligonucleotide that hybridizes to a polynucleotide selected from the group consisting of (a) a polynucleotide encoding a protein that comprises the amino acid sequence of SEQ ID NO:2, 56, or 58, (b) a polynucleotide comprising the sequence of SEQ ID NO:1, (c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) or (b), (d) a polynucleotide having a nucleic acid sequence that deviates from the nucleic acid sequences specified in (a)-(c) due to the degeneration of the genetic code, and (e) a polynucleotide that represents a fragment, derivative, or allelic variation of a nucleic acid sequence specified in (a)-(d).
Dependencies are inferred from the claim text.